Tevogen Stock Surges on Expanded Microsoft AI Collaboration
Tevogen Bio (NASDAQ:TVGN) stock jumped nearly 26% post-market after the company announced it has expanded its relationship with Microsoft (NASDAQ:MSFT) to broaden their AI-focused collaboration and build its PredicTcell technology for predictive precision T cell targeting.
The Tevogen.AI initiative will integrate Microsoft's AI tools and Azure cloud platform to expand Tevogen's (NASDAQ:TVGN) ExacTcell preclinical pipeline. The initiative will also aim to develop proprietary algorithms to decode HLA-T cell interactions, according to a statement.
The company added it is also investigating potential treatments for HPV and identifying cytotoxic T cell targets to select for a clinical trial for its first oncology drug candidate, TVGN 920.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10